Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Ovarian Neoplasms

  Free Subscription


28.06.2021

1 Br J Cancer
2 Gynecol Oncol
1 Int J Cancer
2 Lancet Oncol
2 Oncogene
2 PLoS One
1 Proc Natl Acad Sci U S A


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Br J Cancer

  1. FENG JL, Dixon-Suen SC, Jordan SJ, Webb PM, et al
    Statin use and survival among women with ovarian cancer: an Australian national data-linkage study.
    Br J Cancer. 2021 Jun 16. pii: 10.1038/s41416-021-01460.
    PubMed         Abstract available


    Gynecol Oncol

  2. BALDEWPERSAD TEWARIE NMS, van Driel WJ, van Ham M, Wouters MW, et al
    Postoperative outcomes of primary and interval cytoreductive surgery for advanced ovarian cancer registered in the Dutch Gynecological Oncology Audit (DGOA).
    Gynecol Oncol. 2021 Jun 16. pii: S0090-8258(21)00436.
    PubMed         Abstract available

  3. JIANG C, Li Z
    Performance validation of the Mayo triage algorithm applied to individualize surgical management of advanced epithelial ovarian cancer.
    Gynecol Oncol. 2021 Jun 16. pii: S0090-8258(21)00483.
    PubMed         Abstract available


    Int J Cancer

  4. DARELIUS A, Kristjansdottir B, Dahm-Kahler P, Strandell A, et al
    Risk of epithelial ovarian cancer Type I and II after hysterectomy, salpingectomy and tubal ligation - A nationwide case control study.
    Int J Cancer. 2021 Jun 21. doi: 10.1002/ijc.33714.
    PubMed         Abstract available


    Lancet Oncol

  5. BARBER E, Matei D
    Immunotherapy in ovarian cancer: we are not there yet.
    Lancet Oncol. 2021 Jun 15. pii: S1470-2045(21)00303.
    PubMed        

  6. PUJADE-LAURAINE E, Fujiwara K, Ledermann JA, Oza AM, et al
    Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
    Lancet Oncol. 2021 Jun 15. pii: S1470-2045(21)00216.
    PubMed         Abstract available


    Oncogene

  7. ZHANG J, Guan W, Xu X, Wang F, et al
    A novel homeostatic loop of sorcin drives paclitaxel-resistance and malignant progression via Smad4/ZEB1/miR-142-5p in human ovarian cancer.
    Oncogene. 2021 Jun 23. pii: 10.1038/s41388-021-01891.
    PubMed         Abstract available

  8. WU Y, Guo Q, Ju X, Hu Z, et al
    HNRNPH1-stabilized LINC00662 promotes ovarian cancer progression by activating the GRP78/p38 pathway.
    Oncogene. 2021 Jun 19. pii: 10.1038/s41388-021-01884.
    PubMed         Abstract available


    PLoS One

  9. OYAMA Y, Shigeta S, Tokunaga H, Tsuji K, et al
    CHD4 regulates platinum sensitivity through MDR1 expression in ovarian cancer: A potential role of CHD4 inhibition as a combination therapy with platinum agents.
    PLoS One. 2021;16:e0251079.
    PubMed         Abstract available

  10. GUI T, Yao C, Jia B, Shen K, et al
    Identification and analysis of genes associated with epithelial ovarian cancer by integrated bioinformatics methods.
    PLoS One. 2021;16:e0253136.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  11. GU S, Lheureux S, Sayad A, Cybulska P, et al
    Computational modeling of ovarian cancer dynamics suggests optimal strategies for therapy and screening.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: